Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit.
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study
Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study
Critically ill patients with COVID-19 are associated with a higher risk of severe complications and need to receive an intensive level of treatments, and these patients are investigated in a multicenter prospective observational study.
Protecting healthcare personnel from 2019-nCoV infection risks: lessons and suggestions
Based on literature search and interviews with some HCP working at Wuhan, capital city of Hubei, some of the effective measures taken to reduce infection among HCP are summarized, and suggestions for improving occupational safety during an infectious disease outbreak are made.
Tracheostomy in 80 COVID-19 Patients: A Multicenter, Retrospective, Observational Study
In patients with SARS-CoV-2 pneumonia, tracheostomies were feasible to conduct by ICU physician at bedside with few major complications and were associated with an increased mortality rate.
Extracorporeal Membrane Oxygenation for SARS-CoV-2 Acute Respiratory Distress Syndrome: A Retrospective Study From Hubei, China
In Hubei, China, the ECMO-treated patients infected by SARS-CoV-2 were of a broad age range and with severe hypoxemia, and the durations of ECMO support, accompanied with increased complications, were relatively long.
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
The findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19 and patients should continue previous anti-hypertensive therapy until further evidence is available.
A Novel Risk-Stratification Models of the High-Flow Nasal Cannula Therapy in COVID-19 Patients With Hypoxemic Respiratory Failure
Aged patients with lower ROX index, thrombocytopenia, and elevated IL-6 values are at increased risk of HFNC failure, and early stratified COVID-19 patients with HFNC therapy into relevant risk categories are stratified.